Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients
Table 1
Demographic and clinical characteristics of 100 AOC patients.
Items
Value
Clinical characteristics
Age (median, range) (y)
58.5 (28-87)
KPS score (median, range)
80 (50-100)
History of chemotherapy (, %)
Yes
52 (52.0)
No
48 (48.0)
Histopathology (, %)
Serous carcinoma
91 (91.0)
Other types
9 (9.0)
Cycles of SC before surgery (median, range)
3 (0-45)
Cycles of IPC before surgery (median, range)
1 (0-9)
Cycles of SC after surgery (median, range)
4 (0-26)
Cycles of IPC after surgery (median, range)
6 (0-8)
SC before surgery (, %)
48 (48)
IPC before surgery (, %)
16 (16)
SC after surgery (, %)
76 (76)
IPC after surgery (, %)
46 (46)
CRS+HIPEC relevant parameters
Organ regions resected (, %)
1-3 resections
39 (39.0)
>4 resections
61 (61.0)
Peritoneal regions resected (, %)
0-3 resections
37 (37.0)
4-6 resections
40 (40.0)
>6 resections
23 (23.0)
Number of anastomosis (, %)
0-1
34 (34.0)
≥1
66 (66.0)
PCI score (, %)
≤19
53 (53.0)
>19
47 (47.0)
CC score (, %)
0-1
79 (79.0)
2-3
21 (21.0)
Lymph node dissection (, %)
Pelvic lymph node
100 (100)
Abdominal aortic lymph node
68 (68)
Iliac lymph nodes
100 (100)
Fluid output volume at surgery (median, range)
Blood loss (ml)
550 (0-3,000)
Urine output (ml)
1,500 (300-4,500)
Ascites (ml)
270 (0-8,000)
≤1000 (, %)
68 (68.0)
>1000 (, %)
32 (32.0)
Fluid intake volume at surgery (median, range)
Plasma (ml)
600 (0-4,000)
RBC (U)a
2 (0-12.0)
Other fluids (ml)b
6,735 (100-13,950)
CRS+HIPEC duration (median, range) (min)
600 (80-910)
Stay in hospital (median, range) (d)
27 (0-120)
a ml. bIncluding crystalloid, colloidal fluid injection volume.
